Stelara Side Effects
Generic Name: ustekinumab
Note: This page contains side effects data for the generic drug ustekinumab. It is possible that some of the dosage forms included below may not apply to the brand name Stelara.
It is possible that some side effects of Stelara may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.
For the Consumer
Applies to ustekinumab: subcutaneous solution
As well as its needed effects, ustekinumab (the active ingredient contained in Stelara) may cause unwanted side effects that require medical attention.
If any of the following side effects occur while taking ustekinumab, check with your doctor immediately:More common
- Cough or hoarseness
- fever or chills
- lower back or side pain
- painful or difficult urination
- Body aches or pain
- difficulty with breathing
- ear congestion
- loss of voice
- nasal congestion
- runny nose
- sore throat
- unusual tiredness or weakness
- Blurred or loss of vision
- clear or bloody discharge from the nipple
- difficult or frequent urination
- dimpling of the breast skin
- disturbed color perception
- double vision
- halos around lights
- inverted nipple
- itching, pain, redness, swelling, tenderness, or warmth on the skin
- lump in the breast or under the arm
- night blindness
- overbright appearance of lights
- persistent crusting or scaling of the nipple
- redness or swelling of the breast
- sore on the skin of the breast that does not heal
- tunnel vision
- Difficulty with swallowing
- fast heartbeat
- hives or welts
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- redness of the skin
- tightness in the chest
Some ustekinumab side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:More common
- Muscle aches
- Back pain
- bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
- difficulty with moving
- joint pain
- muscle cramps
- muscle pain or stiffness
- swollen joints
For Healthcare Professionals
Applies to ustekinumab: subcutaneous solution
Respiratory side effects including nasopharyngitis (up to 8%), upper respiratory tract infection (up to 5%), and pharyngolaryngeal pain (up to 2%) have been reported.
Nervous system side effects including headache (5%) and dizziness (2%) have been reported.
Other side effects including cellulitis and other infections have been reported.
In the placebo-controlled period of clinical studies of psoriasis subjects, 27% of ustekinumab-treated subjects reported infections compared with 24% of placebo-treated subjects. Serious infections occurred in 0.3% of ustekinumab-treated subjects and in 0.4% of placebo-treated subjects.
In the controlled and non-controlled portions of psoriasis clinical trials, 72.3% of ustekinumab-treated subjects reported infections. Serious infections were reported in 2.8% of subjects.
General side effects including fatigue (3%) have been reported.
Gastrointestinal side effects including diarrhea (2%) have been reported.
Musculoskeletal side effects including back pain (up to 2%) and myalgia (1%) have been reported.
Local side effects including injection site erythema (up to 2%) and other injection site reactions (pain, swelling, pruritus, induration, hemorrhage, bruising, and irritation) have been reported.
Dermatologic side effects including pruritus (up to 2%) have been reported. Postmarketing reports have included pustular and erythrodermic psoriasis.
Psychiatric side effects have included depression (1%).
In the controlled and non-controlled portions of psoriasis clinical trials 1.7% of ustekinumab (the active ingredient contained in Stelara) treated subjects reported malignancies (excluding non-melanoma skin cancers). Other than non-melanoma skin cancers (1.5%), the most frequently observed malignancies were prostate, colorectal, melanoma in situ, and breast.
Oncologic side effects including malignancies and postmarketing reports of rapidly appearing, multiple cutaneous squamous cell carcinoma have been reported.
Hypersensitivity side effects have included postmarketing reports of serious hypersensitivity reactions (including anaphylaxis and angioedema, and other hypersensitivity reactions (including rash and urticaria).
More about Stelara (ustekinumab)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.